These findings suggest the potential feasibility of using endothelin receptor antagonists to treat GBM and breast cancer, and that fine-tuning of the ETAR and ETBR balance is crucial for maximum cytotoxicity while sparing normal cells. This evidence concerns the gene EDNRA and breast cancer.